These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 16672325)

  • 1. Complications of mitomycin C therapy in 100 eyes with ocular surface neoplasia.
    Khong JJ; Muecke J
    Br J Ophthalmol; 2006 Jul; 90(7):819-22. PubMed ID: 16672325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topical 0.002% mitomycin C for the treatment of conjunctival-corneal intraepithelial neoplasia and squamous cell carcinoma.
    Prabhasawat P; Tarinvorakup P; Tesavibul N; Uiprasertkul M; Kosrirukvongs P; Booranapong W; Srivannaboon S
    Cornea; 2005 May; 24(4):443-8. PubMed ID: 15829803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topical mitomycin C for the treatment of conjunctival and corneal epithelial dysplasia and neoplasia.
    Wilson MW; Hungerford JL; George SM; Madreperla SA
    Am J Ophthalmol; 1997 Sep; 124(3):303-11. PubMed ID: 9439356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitomycin C treatment for conjunctival-corneal intraepithelial neoplasia: a multicenter experience.
    Frucht-Pery J; Sugar J; Baum J; Sutphin JE; Pe'er J; Savir H; Holland EJ; Meisler DM; Foster JA; Folberg R; Rozenman Y
    Ophthalmology; 1997 Dec; 104(12):2085-93. PubMed ID: 9400769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of ocular surface squamous neoplasia with Mitomycin C.
    Gupta A; Muecke J
    Br J Ophthalmol; 2010 May; 94(5):555-8. PubMed ID: 20447963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Topical Mitomycin C as a therapy of conjunctival tumours].
    Schallenberg M; Niederdräing N; Steuhl KP; Meller D
    Ophthalmologe; 2008 Aug; 105(8):777-84. PubMed ID: 18618124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topical mitomycin C for extensive, recurrent conjunctival-corneal squamous cell carcinoma.
    Shields CL; Naseripour M; Shields JA
    Am J Ophthalmol; 2002 May; 133(5):601-6. PubMed ID: 11992855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mitomycin C therapy for conjunctival-corneal intraepithelial neoplasia.
    Papandroudis AA; Dimitrakos SA; Stangos NT
    Cornea; 2002 Oct; 21(7):715-7. PubMed ID: 12352093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topical mitomycin C chemotherapy for conjunctival melanoma and PAM with atypia.
    Finger PT; Czechonska G; Liarikos S
    Br J Ophthalmol; 1998 May; 82(5):476-9. PubMed ID: 9713051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of topical chemotherapy for primary acquired melanosis and malignant melanoma of the conjunctiva and cornea: review of the evidence and recommendations for treatment.
    Chalasani R; Giblin M; Conway RM
    Clin Exp Ophthalmol; 2006; 34(7):708-14. PubMed ID: 16970772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of mitomycin C in the treatment of corneal conjunctival intraepithelial neoplasia.
    Daniell M; Maini R; Tole D
    Clin Exp Ophthalmol; 2002 Apr; 30(2):94-8. PubMed ID: 11886411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of diffuse ocular surface squamous neoplasia: efficacy and complications of topical chemotherapy.
    Rudkin AK; Dempster L; Muecke JS
    Clin Exp Ophthalmol; 2015; 43(1):20-5. PubMed ID: 24995542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topical mitomycin chemotherapy for conjunctival malignant melanoma and primary acquired melanosis with atypia: clinical experience with histopathologic observations.
    Demirci H; McCormick SA; Finger PT
    Arch Ophthalmol; 2000 Jul; 118(7):885-91. PubMed ID: 10900099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topical mitomycin C for the treatment of conjunctival and corneal epithelial dysplasia and neoplasia.
    Gebhardt DO
    Am J Ophthalmol; 1998 Mar; 125(3):416-7. PubMed ID: 9512172
    [No Abstract]   [Full Text] [Related]  

  • 15. Safety and efficacy of topical interferon alpha 2B and mitomycin C for localized conjunctival intraepithelial neoplasia: long-term report of their pharmacological safety and efficacy.
    Alvarado-Castillo B; Santa Cruz-Pavlovich FJ; Gonzalez-Castillo C; Vidal-Paredes IA; Garcia-Benavides L; Rosales-Gradilla ME; Navarro-Partida J
    BMC Ophthalmol; 2023 Jul; 23(1):335. PubMed ID: 37501105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term results of topical mitomycin C 0.02% for primary and recurrent conjunctival-corneal intraepithelial neoplasia.
    Ballalai PL; Erwenne CM; Martins MC; Lowen MS; Barros JN
    Ophthalmic Plast Reconstr Surg; 2009; 25(4):296-9. PubMed ID: 19617789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tear function and ocular surface changes with topical mitomycin (MMC) treatment for primary corneal intraepithelial neoplasia.
    Dogru M; Erturk H; Shimazaki J; Tsubota K; Gul M
    Cornea; 2003 Oct; 22(7):627-39. PubMed ID: 14508259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The intraoperative use of mitomycin-C in excision of ocular surface neoplasia with or without limbal autograft transplantation.
    Siganos CS; Kozobolis VP; Christodoulakis EV
    Cornea; 2002 Jan; 21(1):12-6. PubMed ID: 11805500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impression cytology following mitomycin C therapy for ocular surface squamous neoplasia.
    McKelvie PA; Daniell M
    Br J Ophthalmol; 2001 Sep; 85(9):1115-9. PubMed ID: 11520767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of conjunctival intraepithelial neoplasia with topical mitomycin C 0.02%].
    Ramos-López JF; Martínez-Costa Pérez R; Cisneros Lanuza AL; Francés Muñoz E; Monte Boque E; Muñoz Gómez MC; López-Sánchez EV; Menezo Rozalén JL
    Arch Soc Esp Oftalmol; 2004 Aug; 79(8):375-8. PubMed ID: 15306963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.